CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-14-0793
Full Text
Open PDFAbstract
Available in full text
Date
April 7, 2015
Authors
Publisher
American Association for Cancer Research (AACR)